MX9701111A - SPECIFIC UNION SEQUENCE OLIGOMERS FOR NUCLEIC ACIDS AND THEIR USE IN ANTI-SENSE STRATEGIES. - Google Patents

SPECIFIC UNION SEQUENCE OLIGOMERS FOR NUCLEIC ACIDS AND THEIR USE IN ANTI-SENSE STRATEGIES.

Info

Publication number
MX9701111A
MX9701111A MX9701111A MX9701111A MX9701111A MX 9701111 A MX9701111 A MX 9701111A MX 9701111 A MX9701111 A MX 9701111A MX 9701111 A MX9701111 A MX 9701111A MX 9701111 A MX9701111 A MX 9701111A
Authority
MX
Mexico
Prior art keywords
nucleic acids
specific union
sequence oligomers
sense strategies
oligomers
Prior art date
Application number
MX9701111A
Other languages
Spanish (es)
Other versions
MXPA97001111A (en
Inventor
Piet Andre Maurits Herdewijn
Arthur Albert Edgard Aerschot
Original Assignee
Stichting Rega V Z W
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stichting Rega V Z W filed Critical Stichting Rega V Z W
Publication of MX9701111A publication Critical patent/MX9701111A/en
Publication of MXPA97001111A publication Critical patent/MXPA97001111A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion se relaciona con oligomeros que consisten completa o parcialmente de análogos nucleosidicos de 1,5-anhidrohexitol representados por la formula general (I), en la cual B es un anillo heterocíclico, el cual se derivo de una base pirimídica o purica, tal como la citosina, 5-metilcitosina, uracilo y timina, o derivados desaza de las mismas o adenina, guanina, 2,6-diaminopurina, hipoxantina y xantina, o derivados desaza de las mismas.This invention relates to oligomers consisting entirely or partially of 1,5-anhydrohexitol nucleoside analogues represented by the general formula (I), in which B is a heterocyclic ring, which is derived from a pyrimidic or pure base, such such as cytosine, 5-methylcytosine, uracil and thymine, or desaza derivatives thereof or adenine, guanine, 2,6-diaminopurine, hypoxanthine and xanthine, or desaza derivatives thereof.

MXPA/A/1997/001111A 1994-08-17 1997-02-12 Specific oligomeros of sequence union nucleic paraacidos and its use in antisent strategies MXPA97001111A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
NL94202342.5 1994-08-17
EP94202342 1994-08-17
US49515295A 1995-06-27 1995-06-27
US495152 1995-06-27
PCT/EP1995/003248 WO1996005213A1 (en) 1994-08-17 1995-08-14 Sequence-specific binding oligomers for nucleic acids and their use in antisense strategies

Publications (2)

Publication Number Publication Date
MX9701111A true MX9701111A (en) 1998-03-31
MXPA97001111A MXPA97001111A (en) 1998-10-15

Family

ID=

Also Published As

Publication number Publication date
NO970716L (en) 1997-02-17
NZ292140A (en) 1998-02-26
JP2000505778A (en) 2000-05-16
EP0777676A1 (en) 1997-06-11
FI970598A0 (en) 1997-02-12
AU3384595A (en) 1996-03-07
FI970598A7 (en) 1997-02-12
HUT77509A (en) 1998-05-28
FI970598L (en) 1997-02-12
CN1158618A (en) 1997-09-03
WO1996005213A1 (en) 1996-02-22
CA2196306A1 (en) 1996-02-22

Similar Documents

Publication Publication Date Title
PA8483101A1 (en) CHEMICAL COMPOUNDS
DK0679657T3 (en) Nucleosides and oligonucleotides with 2'-ether groups
NZ507913A (en) Novel nucleosides having bicyclic sugar moiety
ATE432284T1 (en) NUCLEOTIDES CONTAINING A RIGID LINKER
DK1280813T3 (en) Antiviral pyrimidine nucleoside analogues
MX9203682A (en) DERIVATIVES OF 9-PURINYL PHOSPHONIC ACID.
DK1165560T3 (en) 2-Hydroxymethylcyclopropylidene methylpurines as antivirals
ATE124412T1 (en) ANTIVIRUS DERIVATIVES OF (PHOSPHONEMETHOXY)METHOXY PURINE/PYRIMIDINE.
DE69320945D1 (en) ANTIVIRAL NUCLEOSIDE ANALOGS
ES2166081T3 (en) NUCLEOSIDE DERIVATIVES WITH PHOTOLABILE PROTECTIVE GROUPS.
DK0720604T3 (en) Conformationally locked nucleoside analogs
NO970716L (en) Sequence-specific binding oligomers for nucleic acids and their use in antisense strategies
DK1068209T3 (en) Process for the preparation of purine derivatives and their intermediates
PT1490368E (en) 2,2-bis(hydroxymethyl)cyclopropylidenemethyl - purines and -pyrimidines as antiviral agents
DE60335805D1 (en) PROCESS FOR THE PREPARATION OF 1,3-DIOXOLANE NUCLEOSIDES
MY127470A (en) Process for the synthesis of chloropurine intermediates
NO974512D0 (en) Method for Synthesis of Nucleoside Analogs
AR003454A1 (en) PIRIMIDINE NUCLEOSIDE DERIVATIVES, A PROCEDURE FOR THEIR PREPARATION AND THE USE OF THE SAME AS ANTIVIRAL AGENTS.
RU97119150A (en) INHIBITOR OF HUMAN IMMUNE DEFICIENCY VIRUS REPRODUCTION
AR029194A1 (en) NUCLEOSIDO THAT HAS A FRACTION OF OLIGONUCLEOTIDE BICYCLE SUGAR AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT